176 related articles for article (PubMed ID: 1331448)
1. Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product.
Williams PD; Bock MG; Tung RD; Garsky VM; Perlow DS; Erb JM; Lundell GF; Gould NP; Whitter WL; Hoffman JB
J Med Chem; 1992 Oct; 35(21):3905-18. PubMed ID: 1331448
[TBL] [Abstract][Full Text] [Related]
2. In vitro pharmacological profile of a novel structural class of oxytocin antagonists.
Pettibone DJ; Clineschmidt BV; Lis EV; Reiss DR; Totaro JA; Woyden CJ; Bock MG; Freidinger RM; Tung RD; Veber DF
J Pharmacol Exp Ther; 1991 Jan; 256(1):304-8. PubMed ID: 1988661
[TBL] [Abstract][Full Text] [Related]
3. A structurally unique, potent, and selective oxytocin antagonist derived from Streptomyces silvensis.
Pettibone DJ; Clineschmidt BV; Anderson PS; Freidinger RM; Lundell GF; Koupal LR; Schwartz CD; Williamson JM; Goetz MA; Hensens OD
Endocrinology; 1989 Jul; 125(1):217-22. PubMed ID: 2544402
[TBL] [Abstract][Full Text] [Related]
4. Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modifications.
Freidinger RM; Williams PD; Tung RD; Bock MG; Pettibone DJ; Clineschmidt BV; DiPardo RM; Erb JM; Garsky VM; Gould NP
J Med Chem; 1990 Jul; 33(7):1843-5. PubMed ID: 2163451
[No Abstract] [Full Text] [Related]
5. 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.
Williams PD; Anderson PS; Ball RG; Bock MG; Carroll L; Chiu SH; Clineschmidt BV; Culberson JC; Erb JM; Evans BE
J Med Chem; 1994 Mar; 37(5):565-71. PubMed ID: 8126695
[TBL] [Abstract][Full Text] [Related]
6. Bradykinin agonist activity of a novel, potent oxytocin antagonist.
Pettibone DJ; Clineschmidt BV; Lis EV; Ransom RW; Totaro JA; Young GS; Bock MG; Freidinger RM; Veber DF; Williams PD
Eur J Pharmacol; 1991 Apr; 196(3):233-7. PubMed ID: 1893911
[TBL] [Abstract][Full Text] [Related]
7. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
8. Design of novel bicyclic analogues derived from a potent oxytocin antagonist.
Flouret G; Chaloin O; Borovickova L; Slaninová J
J Pept Sci; 2006 Jun; 12(6):412-9. PubMed ID: 16432806
[TBL] [Abstract][Full Text] [Related]
9. Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide.
Bock MG; DiPardo RM; Williams PD; Pettibone DJ; Clineschmidt BV; Ball RG; Veber DF; Freidinger RM
J Med Chem; 1990 Sep; 33(9):2321-3. PubMed ID: 2167976
[No Abstract] [Full Text] [Related]
10. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.
Manning M; Miteva K; Pancheva S; Stoev S; Wo NC; Chan WY
Int J Pept Protein Res; 1995; 46(3-4):244-52. PubMed ID: 8537178
[TBL] [Abstract][Full Text] [Related]
11. Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays.
Chan WY; Wo NC; Stoev ST; Cheng LL; Manning M
Exp Physiol; 2000 Mar; 85 Spec No():7S-18S. PubMed ID: 10795902
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of oxytocin in rats and pregnant rhesus monkeys by the novel cyclic hexapeptides, L-366,682 and L-366,948.
Clineschmidt BV; Pettibone DJ; Reiss DR; Lis EV; Haluska GJ; Novy MJ; Cook MJ; Cukierski MA; Kaufman MJ; Bock MG
J Pharmacol Exp Ther; 1991 Mar; 256(3):827-32. PubMed ID: 2005582
[TBL] [Abstract][Full Text] [Related]
13. The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists.
Chan WY; Wo NC; Manning M
Am J Obstet Gynecol; 1996 Nov; 175(5):1331-5. PubMed ID: 8942510
[TBL] [Abstract][Full Text] [Related]
14. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
Chan WY; Wo NC; Cheng LL; Manning M
J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
[TBL] [Abstract][Full Text] [Related]
15. Analogues of arginine vasopressin modified in position 2 or 3 with naphthylalanine: selective antagonists of oxytocin in-vitro.
Sobocińska M; Lempicka E; Konieczna E; Derdowska I; Lammek B; Melhem S; Kozik W; Janecka J; Janecki M; Trzeciak HI
J Pharm Pharmacol; 2000 Sep; 52(9):1105-12. PubMed ID: 11045891
[TBL] [Abstract][Full Text] [Related]
16. Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.
Quattropani A; Dorbais J; Covini D; Pittet PA; Colovray V; Thomas RJ; Coxhead R; Halazy S; Scheer A; Missotten M; Ayala G; Bradshaw C; De Raemy-Schenk AM; Nichols A; Cirillo R; Tos EG; Giachetti C; Golzio L; Marinelli P; Church DJ; Barberis C; Chollet A; Schwarz MK
J Med Chem; 2005 Dec; 48(24):7882-905. PubMed ID: 16302826
[TBL] [Abstract][Full Text] [Related]
17. Structural requirements of the oxytocin receptor in rat uterus. Free-Wilson analysis in a series of competitive oxytocin inhibitors.
Pliska V; Heiniger J
Int J Pept Protein Res; 1988 Jun; 31(6):520-36. PubMed ID: 2842268
[TBL] [Abstract][Full Text] [Related]
18. Oxytocin antagonists with changes in the Asn5 position shed light on hormone-oxytocin receptor interactions.
Hill PS; Chan WY; Hruby VJ
Int J Pept Protein Res; 1991 Jul; 38(1):32-7. PubMed ID: 1657804
[TBL] [Abstract][Full Text] [Related]
19. Conformationally constrained o-tolylpiperazine camphorsulfonamide oxytocin antagonists. Structural modifications that provide high receptor affinity and suggest a bioactive conformation.
Williams PD; Ball RG; Clineschmidt BV; Culberson JC; Erb JM; Freidinger RM; Pawluczyk JM; Perlow DS; Pettibone DJ; Veber DF
Bioorg Med Chem; 1994 Sep; 2(9):971-85. PubMed ID: 7712132
[TBL] [Abstract][Full Text] [Related]
20. Progress in the development of oxytocin antagonists for use in preterm labor.
Williams PD; Bock MG; Evans BE; Freidinger RM; Pettibone DJ
Adv Exp Med Biol; 1998; 449():473-9. PubMed ID: 10026841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
